Day One Biopharmaceuticals
Cancer drug development comes of age. Follow.
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | 16 % | 56 % | 58 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | (179 %) | (112 %) | (50 %) | 1 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | (73 %) | (95 %) | (35 %) | 4 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | 174 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Day One Biopharmaceuticals focuses on developing innovative treatments for pediatric cancer through a collaborative approach involving multiple stakeholders. The company operates in the biopharmaceutical industry, targeting unmet medical needs in pediatric oncology. Its business model revolves around drug development, clinical trials, and partnerships with healthcare providers and research institutions. Revenue is generated through the commercialization of successful drug candidates and strategic alliances. Day One Biopharmaceuticals serves patients, healthcare providers, and research communities, aiming to improve outcomes for children with cancer.
Keywords: Pediatric cancer, drug development, clinical trials, biopharmaceuticals, oncology, collaborative research, healthcare partnerships, unmet medical needs, commercialization, strategic alliances.